Opus Genetics presented interim clinical data from its gene therapy programs at the Retina in Rio 2026 conference. For OPGx-BEST1, Cohort 1 results showed improved retinal sensitivity in three of four evaluable participants (75%), with structural improvements linked to functional gains. For OPGx-LCA5, sustained improvements in visual acuity and light sensitivity were observed through 24 months in adults and six months in pediatric participants. The Phase 3 trial for OPGx-LCA5 is fully enrolled, with dosing initiation expected in the fourth quarter of 2026. Opus Genetics operates as a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases.
